EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy of Different Doses of Intra‐Articular Tranexamic Acid for Reducing Blood Loss and Lower Limb Swelling After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial

Shuwei Ye, Yue Luo, Qianhao Li, Lijun Cai, Pengde Kang iD

Orthopaedic Surgery · 2025

DOI: 10.1111/os.14317 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Orthopaedic Surgery, 2025. Verfasst von Shuwei Ye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics Surgery, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Tranexamic Acid, Arthroplasty, Replacement, Knee, Antifibrinolytic Agents, Blood Loss, Surgical. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Both blood loss and lower extremity swelling after total knee arthroplasty (TKA) can affect a patient's postoperative recovery. The aim of this trial was to investigate whether different doses of intra‐articular tranexamic acid (TXA) can reduce blood loss and postoperative lower limb swelling.

Methods

In a prospective, randomized‐controlled trial, a total of 225 patients were randomly assigned to three groups from September 2020 through January 2021: intra‐articular injections of 3 g, 1 g of TXA, or placebo (saline solution). The primary outcome indicators were perioperative blood loss and decreased hemoglobin levels. The secondary outcome indicators were lower extremity swelling, functional recovery indicators (hospital for special surgery [HSS] scores, range of motion), visual analog scale [VAS] scores, and transfusion rates and safety outcomes, including thromboembolic events, incidence of wound‐related complications, and length of hospital stay. One‐way analysis of variance (ANOVA), post hoc Bonferroni correction, Pearson chi‐square test and Fisher exact test were used for statistical analysis.

Results

Postoperative blood loss was lower in the 1 and 3 g TXA groups (754.00 ± 409.67 mL and 568.70 ± 408.27 mL, respectively) than in the placebo group (977.32 ± 418.69 mL) ( p < 0.001). The maximum postoperative decrease in hemoglobin was lower in the 1 and 3 g TXA groups (2.4 ± 0.9 and 1.8 ± 0.9 g/dL, respectively) than in the placebo group (3.1 ± 1.2 g/dL) ( p < 0.001). On postoperative Days 1, 2, and 3, the TXA group presented significantly reduced thigh, suprapatellar, and calf swelling and significantly reduced pain scores during exercise. Compared with that in the low‐dose group, perioperative blood loss was further reduced in the high‐dose TXA group ( p = 0.006). However, while patients in the TXA group had improved pain scores, Hospital for Special Surgery scores, and joint range of motion at postoperative rest, these differences were not statistically significant. There were no significant differences in thromboembolic events or complication rates among the three groups.

Conclusion

Topical TXA in total knee arthroplasty was effective in reducing postoperative blood loss by 24%–43% and in reducing postoperative lower extremity swelling and pain during exercise. Higher doses (3 g) of TXA further controlled perioperative blood loss without affecting postoperative lower extremity swelling, and there was no increase in the incidence of related complications during follow‐up. Trial Registration: This study was a single‐center, prospective, randomized controlled trial (RCT). The trial was approved by the Clinical Trials and Biomedical Ethics Committee at our institution (number: 2018.676), all participants provided written informed consent, and the trial was prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2000035271)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidArthroplasty, Replacement, KneeAntifibrinolytic AgentsBlood Loss, SurgicalEdemaHumansProspective StudiesMaleFemaleAgedMiddle AgedInjections, Intra-ArticularLower ExtremityDose-Response Relationship, Drug

Stichwörter der Autor:innen

blood lossswellingtotal knee arthroplastytranexamic acid

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Orthopaedics Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

ORCID-Profile: Pengde Kang

Förderung

  • 1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University

Zitieren

APA

Ye, S., Luo, Y., Li, Q., Cai, L., & Kang, P. (2025). Efficacy of Different Doses of Intra‐Articular Tranexamic Acid for Reducing Blood Loss and Lower Limb Swelling After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial. Orthopaedic Surgery. https://doi.org/10.1111/os.14317

Vancouver

Ye S, Luo Y, Li Q, Cai L, Kang P. Efficacy of Different Doses of Intra‐Articular Tranexamic Acid for Reducing Blood Loss and Lower Limb Swelling After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial. Orthopaedic Surgery. 2025. doi:10.1111/os.14317

BibTeX
@article{Ye2025,
  author = {Ye, Shuwei and Luo, Yue and Li, Qianhao and Cai, Lijun and Kang, Pengde},
  title = {Efficacy of Different Doses of Intra‐Articular Tranexamic Acid for Reducing Blood Loss and Lower Limb Swelling After Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial},
  journal = {Orthopaedic Surgery},
  year = {2025},
  doi = {10.1111/os.14317}
}
Kostenlos starten →